Literature DB >> 7686617

Mapping of the p53 and mdm-2 interaction domains.

J Chen1, V Marechal, A J Levine.   

Abstract

The 90-kDa cellular protein encoded by the mouse mdm-2 oncogene binds to the p53 protein in vivo and inhibits its transactivation function (J. Momand, G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine, Cell 69:1237-1245, 1992). cDNA clones encoding the human homolog of the mdm-2 protein (also called hdm-2) were isolated from a HeLa cell cDNA library. A series of monoclonal antibodies have been generated against human mdm-2 protein, and the epitopes recognized by these antibodies have been mapped. By construction of a series of deletion mutants, the region of the mdm-2 protein that is critical for complex formation with the p53 protein has been mapped to the N-terminal portion of the human mdm-2 protein. Interestingly, a monoclonal antibody with an epitope located in this same region failed to immunoprecipitate the mdm-2-p53 complex and appeared to recognize only free mdm-2 protein. The domain of the p53 protein that is sufficient for interaction with human mdm-2 protein has been mapped to the N-terminal 52 amino acid residues of the p53 protein. This region contains the transactivation domain of p53, suggesting that mdm-2 may inhibit p53 function by disrupting its interaction with the general transcription machinery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686617      PMCID: PMC359960          DOI: 10.1128/mcb.13.7.4107-4114.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

1.  A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.

Authors:  H W Stürzbecher; R Brain; C Addison; K Rudge; M Remm; M Grimaldi; E Keenan; J R Jenkins
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

2.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

Authors:  L R Livingstone; A White; J Sprouse; E Livanos; T Jacks; T D Tlsty
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

3.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

4.  Wild-type p53 activates transcription in vitro.

Authors:  G Farmer; J Bargonetti; H Zhu; P Friedman; R Prywes; C Prives
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

Authors:  Y Yin; M A Tainsky; F Z Bischoff; L C Strong; G M Wahl
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

6.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.

Authors:  J Bargonetti; I Reynisdóttir; P N Friedman; C Prives
Journal:  Genes Dev       Date:  1992-10       Impact factor: 11.361

8.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.

Authors:  J A Mietz; T Unger; J M Huibregtse; P M Howley
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  236 in total

1.  p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.

Authors:  A Ito; C H Lai; X Zhao; S Saito; M H Hamilton; E Appella; T P Yao
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  Identification of a sequence element from p53 that signals for Mdm2-targeted degradation.

Authors:  J Gu; D Chen; J Rosenblum; R M Rubin; Z M Yuan
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  pRB induces Sp1 activity by relieving inhibition mediated by MDM2.

Authors:  T Johnson-Pais; C Degnin; M J Thayer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.

Authors:  M J O'Connor; H Zimmermann; S Nielsen; H U Bernard; T Kouzarides
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Protein kinase CK2 interacts with a multi-protein binding domain of p53.

Authors:  C Götz; P Scholtes; A Prowald; N Schuster; W Nastainczyk; M Montenarh
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

Review 6.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

7.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

8.  MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.

Authors:  E Kobet; X Zeng; Y Zhu; D Keller; H Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

9.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 10.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.